Alternate-Day Buprenorphine Administration. Phase II - 4

National Institutes of Health (NIH)

Status and phase: Completed; Phase 1

Conditions: Opioid-Related Disorders

Treatments: Drug: Buprenorphine

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT00000222

NIDA-06969-4

R01-06969-4

Details and patient eligibility

About

The purpose of this study is to determine if two times a subject's daily maintenance dose will hold for 48 hours without changes in agonist and antagonist effects.

Sex: All

Ages: 28 to 45 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Please contact site for information.